BCL2 and B-cell chronic lymphocytic leukemia: To date, the only FDA approved BH3 mimetic is venetoclax (ABT‐199), a platelet‐sparing selective BCL‐2 inhibitor approved for relapsed CLL.26, 27 MCL‐1 is emerging as a critical prosurvival protein in cancer, with several promising MCL‐1 inhibitors currently in development.28, 29